HOME > TOP STORIES
TOP STORIES
-
ORGANIZATION FPMAJ Chair Hails Innovation-Fueling Policies in Govt Fiscal Plan
July 2, 2015
-
REGULATORY Drug Pricing Tomorrow: Full Interview with Ex-Chuikyo Chairman Endo
July 2, 2015
-
REGULATORY Japan Cabinet OKs Fiscal Policy Guidelines, Marking Dawn of “80% Generic” Era
July 1, 2015
-
TRENDS 3 Major Japan Makers Shed 1,300 Jobs amid Redundancy Programs
June 30, 2015
-
REGULATORY Drug Pricing Tomorrow: MHLW’s Jo Says Price-Maintenance Premium Crucial as Post-Launch Reward for Innovation
June 29, 2015
-
TRENDS “80% Generic” Era Would Further Accelerate Contraction of Market for Long-Listed Drugs
June 29, 2015
-
REGULATORY LDP OKs Economic, Fiscal Policy Guidelines, but Wording on Reference Pricing Could Change
June 26, 2015
-
REGULATORY HTAs Likely to Be Used for Re-Pricing of Listed Medicines
June 25, 2015
-
REGULATORY Drug Pricing Tomorrow: Ex-Chuikyo Chair Urges Pharma to Look at How to Refine Premium, Not Permanent Introduction
June 25, 2015
-
REGULATORY LDP Begins Intraparty Deliberations on Economic, Fiscal Blueprint
June 24, 2015
-
REGULATORY 80% Generic Share “at Early Date,” Essential Drug Supplies Join Draft Fiscal Policy Blueprint
June 23, 2015
-
REGULATORY AMED’s Screening Consortium “Won’t Harm Companies”: Official
June 22, 2015
-
BUSINESS 30 Companies Obtain Listing for Plavix Generics
June 19, 2015
-
REGULATORY Ryukaikon to Push Single-Product, Single-Price Deals in New Proposal Due Out Summer
June 18, 2015
-
REGULATORY Govt Deregulation Panel Calls for Revisiting 14-Day Prescription Limit
June 17, 2015
-
ACADEMIA MHLW Official Restates Difficulty of Moving Up Timeline to Attain 80% Generic Share
June 16, 2015
-
ORGANIZATION Industry Calls for Definition of “Basic Drugs”: FPMAJ Committee
June 15, 2015
-
REGULATORY Takeda Slapped with Business Improvement Order over CASE-J
June 12, 2015
-
REGULATORY Accession Requirements for ICH Assembly Hammered Out at Fukuoka Confab
June 12, 2015
-
ORGANIZATION EFPIA Japan Chief Frets Negative Market Growth amid Pressure on Drug Costs
June 11, 2015
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…